07.01.26 -- In Vivo Gene Editing Is Moving From Promise To Proof

FDA rejection letters reveal validation failures are structural, not technical. Weak lifecycle oversight, robustness, and documentation continue to delay approvals despite clear guidance.

Explore how the latest regulatory updates transform real-world data into a credible evidentiary pathway. Review the new standards for data reliability and hybrid study design.

Take a look at how electrophoresis systems differ in sizing accuracy and why those distinctions matter for assessing high‑molecular‑weight DNA and protecting QC checkpoints across sequencing workflows.

Discover how decades of innovation in sterile connectivity and integrated flow control expertise are empowering manufacturers to solve their most critical fluid transfer challenges.

Annex 1’s updated CCS framework calls for a holistic contamination strategy. Read how manufacturers can apply it to non-sterile sites and legacy facilities using tailored risk-based approaches.

Mycoplasma contamination poses a significant risk to biopharmaceutical products and patient safety. See how implementing a rapid NAT-based testing method can enhance efficiency and quality control.

Move beyond raw data by using heat maps and site-specific limits to identify contamination hotspots. Transform your environmental monitoring into a proactive strategy for operational excellence.

ISO classification decisions shape cleanroom design. Learn how early alignment between process needs, biosafety, and classification can reduce redesign risk while supporting scalable environments.

Early research choices shape outcomes. Focusing on reproducibility, scalability, regulatory fit, and supply stability early cuts risk, prevents delays, and supports smoother development progress.